X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Nitric Oxide is a guanylate cyclase activator, its novel nasal spray formulation is being evaluated for the treatment of recurrent acute rhinosinusitis.
Lead Product(s): Nitric Oxide
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
NONS is currently sold as a medical device under the brand name VirX™ in Thailand, Hong Kong, and Singapore and as a medical device under the brand name of enovid™ in Indonesia, Israel, and Bahrain.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VirX
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Horizons Ventures
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 24, 2022
Details:
Nitric oxide is a naturally occurring molecule known to have antimicrobial properties, including a direct effect on SARS-CoV-2, the virus that causes COVID-19, and its variants.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
After confirmed exposure to COVID-19, infection rate in participants (n=625) who took NONS™ was 6.4% versus 25.6% in the control group (P<0.0001).
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2022
Details:
Phase 3 trial of Nitric oxide reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2022
Details:
Nitric Oxide Nasal Spray has been tested in healthy volunteers and patients as part of UK and Canada clinical trials. Glenmark’s exclusive long-term partnership with SaNOtize to manufacture, market and sell NONS extends.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 02, 2021
Details:
The SaNOtize treatment is based on nitric oxide (NO), a natural nanomolecule produced by the human body with proven anti-microbial properties shown to have a direct effect on SARS-CoV-2, the virus that causes COVID-19.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
Patients with a self-administered Nitric Oxide Nasal Spray (NONS) application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hours.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2021
Details:
The SaNOtize Nitric Oxide Nasal Spray (NONS) is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2021
Details:
SaNOtize is going to study its Nitric Oxide Releasing Solution (NORSTM) in a Phase II trial for the prevention and early treatment of COVID-19.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
